Syncona (SYNC · LSE)
Brilliant Biotech at a Bargain
Syncona is an investment trust that builds and backs breakthrough biotech companies from scratch, offering long-term exposure to high-impact innovation and value creation.
Bull case for Syncona
Significant Discount, Structural Re-Rating Potential
Syncona trades at a steep NAV discount; sector recovery and capital strength offer upside, especially toward its £5bn NAV goal.
Proven Platform with Track Record
Strong historical IRR and disciplined execution support confidence in Syncona’s ability to build, scale, and exit world-leading biotech companies.
Pipeline Maturity and Portfolio Growth
Advancing clinical pipeline and consistent new company formation support Syncona’s long-term NAV growth and ambition to reach £5bn by 2032.
Bear case for Syncona
Clinical Trials and Regulatory Risks
Biotech drug development is high-risk; most candidates fail, and negative trial outcomes can significantly impair Syncona’s concentrated NAV exposure.
Macro Sensitivity and Valuation Swings
Biotech valuations react to macro shifts and discount rates; short-term NAV may fluctuate despite stable long-term development trajectories.
Limited Visibility into Private Valuations
Unquoted holdings lack daily pricing; infrequent updates and opaque valuation methods reduce real-time visibility into Syncona’s true asset value.